Flag of the European Union EU Clinical Trials Register Help

Clinical trials for In situ hybridization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    294 result(s) found for: In situ hybridization. Displaying page 3 of 15.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005002-30 Sponsor Protocol Number: ICORG09-13 Start Date*: 2012-01-05
    Sponsor Name:ICORG-the All Ireland co-operative Oncology Research group
    Full Title: Phase II Lap/Epi: Phase II evaluation of the combination of epirubicin and lapatinib in Her-2 positive, Topoisomerase II alpha positive, metastatic breast cancer.
    Medical condition: Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002207-15 Sponsor Protocol Number: Cardiorete Start Date*: 2011-12-27
    Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO
    Full Title: A prospective study with beta-blockers and ACE-inhibitors in patients operable breast cancer experiencing mild cardiac toxicity during treatment with anthracycline and/or trastuzumab
    Medical condition: patients experiencing mild cardiotoxicity during treatment with anthracycline and/or trastuzumab for operable breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004121-80 Sponsor Protocol Number: Start Date*: 2019-02-05
    Sponsor Name:The Christie Hospital NHS Foundation Trust
    Full Title: A proof of concept, window trial of the IMmunological effects of AveLumab and Aspirin in Triple-Negative Breast Cancer.
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002684-25 Sponsor Protocol Number: SICOG13/01 Start Date*: 2014-03-19
    Sponsor Name:S.I.C.O.G. ONLUS
    Full Title: Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced ...
    Medical condition: Local advanced breast cancer resectable, neoadjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000167-25 Sponsor Protocol Number: UC-0110/1201 Start Date*: 2012-05-29
    Sponsor Name:UNICANCER
    Full Title: A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS...
    Medical condition: Refractory wtKRAS metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004247-23 Sponsor Protocol Number: LUMC201811 Start Date*: 2019-03-22
    Sponsor Name:Leiden University Medical Center
    Full Title: [89Zr]trastuzumab PET/CT imaging of HER2 positive breast cancer for predicting pathologic complete response after neoadjuvant chemotherapy; A multicentre study
    Medical condition: HER2+ breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002801-12 Sponsor Protocol Number: ONT-380-206 Start Date*: 2017-08-07
    Sponsor Name:Seagen Inc.
    Full Title: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastati...
    Medical condition: Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) BE (Completed) DK (Completed) FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002893-11 Sponsor Protocol Number: PASIPHAE Start Date*: 2017-08-14
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced...
    Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-001197-24 Sponsor Protocol Number: D791AC00011 Start Date*: 2006-09-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA™) with erlotinib 150 mg (Tarceva®) in Previously Treated Patients with Locally Advanced o...
    Medical condition: Non-small Cell Lung Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000104-13 Sponsor Protocol Number: B-02 Start Date*: 2005-08-05
    Sponsor Name:Translational Oncology Research International
    Full Title: A multicenter, placebo-controlled, double-blind randomised phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by six cycles of docetaxel, doxorubucin, and cy...
    Medical condition: Stage II or Stage III breast cancer
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000129-12 Sponsor Protocol Number: PCYC-1143-CA Start Date*: 2017-10-10
    Sponsor Name:Pharmacyclics LLC
    Full Title: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) BE (Completed) HU (Completed) ES (Ongoing) NL (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004350-28 Sponsor Protocol Number: VEG20007 Start Date*: 2006-08-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II, Open-Label, Randomized, Multicenter Trial of GW786034 (Pazopanib) in Combination with Lapatinib (GW572016) Compared to Lapatinib Alone as First Line Therapy in Subjects with Advanced or...
    Medical condition: Advanced or metastatic breast cancer with ErbB2 FISH postive tumours
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000134-19 Sponsor Protocol Number: AEZS-108-049 Start Date*: 2012-09-07
    Sponsor Name:Aeterna Zentaris GmbH
    Full Title: A randomised, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
    Medical condition: Histologically confirmed malignancy of breast tissue; estrogen- and progesterone receptor negative, non overexpressing HER2-receptors, LHRH receptor positive tumor status; receptor status determine...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003176-21 Sponsor Protocol Number: TRIO 017 Start Date*: 2008-12-31
    Sponsor Name:Cancer International Research Group
    Full Title: A phase II, open label multicenter trial of panobinostat (LBH589) monotherapy in women with HER2 negative locally recurrent or metastatic breast cancer
    Medical condition: Women with HER-2 negative locally recurrent or metastatic breast cancer;
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001407-23 Sponsor Protocol Number: GEICAM/2015-06 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study).
    Medical condition: Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-002323-25 Sponsor Protocol Number: FBCG-01-2015 Start Date*: 2015-06-25
    Sponsor Name:Finnish Breast Cancer Group
    Full Title: A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive bre...
    Medical condition: Early HER-2 -positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004176-62 Sponsor Protocol Number: CLEE011AIT01 Start Date*: 2018-01-10
    Sponsor Name:NOVARTIS FARMA S.P.A.
    Full Title: A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatmen...
    Medical condition: Hormone receptor-positive (HR+) HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005792-12 Sponsor Protocol Number: GOIRC-06-2020 Start Date*: 2022-04-05
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000394-23 Sponsor Protocol Number: SOLTI-1007 Start Date*: 2012-08-06
    Sponsor Name:SOLTI
    Full Title: A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer
    Medical condition: Patients at Stage I-II HER2-negative breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008276-14 Sponsor Protocol Number: BO22495 Start Date*: 2009-04-27
    Sponsor Name:F. Hoffmann-la Roche Ltd
    Full Title: A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally adv...
    Medical condition: Treatment in patients with HER2-overexpressing locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 23:58:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA